Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 13, 2021 10:24am
142 Views
Post# 32284245

RE:RE:The deal

RE:RE:The dealYes I also think they would like the shares to rise now.
palinc2000 wrote:

The Underwriters motivation will now try to see the SP resume its upward trend

 

palinc2000 wrote: It almost seems like it went like this

Price was set a few weeks ago but there was a prerequisite condition that FDA had to approve the 2 Trials 
There was a maximum discount to the market price ----otherwise the terms had to be renegotiated
The market price was inching up daily after the Jan 6 th PR ..... The Underwriter did not want to be facing the maximum discount clause and acted accordingly in haste ....
So when the 2,75 price was set it was higher than the market price but that was before the Jan 6 PR and management agreed to it 

I may be reading the tea leaves too much but I think the short delay between the PR of Jan 6 and the announcement of the deal yesterday can only be explained by this scenario

 

 



<< Previous
Bullboard Posts
Next >>